We found that 68% of patients had DCIS mRNA expression patterns that matched their clinical scoring for oestrogen receptor (ER/ ESR1), progesterone receptor (PR/ PGR), and human epidermal growth factor receptor 2 (Her2/ ERBB2) (Supplementary Data 1). This evidence concerns the gene ERBB2 and ductal breast carcinoma in situ.